[Federal Register: October 2, 2007 (Volume 72, Number 190)]
[Page 56078-56079]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]



Food and Drug Administration

Science Board to the Food and Drug Administration; Notice of 

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.


    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Science Board to the Food and Drug 
Administration (Science Board).
    General Function of the Committee: The Board shall provide advice 
primarily to the Commissioner and other appropriate officials on 
specific complex and technical issues as well as emerging issues within 
the scientific community in industry and academia. Additionally, the 
Board will provide advice to the agency on keeping pace with technical 
and scientific evolutions in the fields of regulatory science, on 
formulating an appropriate research agenda, and on upgrading it's 
scientific and research facilities to keep pace with these changes. It 
will also provide the means for critical review of agency-sponsored 
intramural and extramural scientific research programs.
    Date and Time: The meeting will be held on October 30, 2007, from 8 
a.m. to 5:30 p.m.
    Location: Washington DC North/Gaithersburg Hilton, 620 Perry Pkwy., 
Gaithersburg, MD 20877, Salons A, B, and C.
    Contact Person: Carlos Pe[ntilde]a, Office of the Commissioner, 
Food and Drug Administration (HF-33), 5600 Fishers Lane, Rockville, MD 
20857, 301-827-6687, carlos.Pe[ntilde]a@fda.hhs.gov, or FDA Advisory 
Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
Washington, DC area), code 3014512603. Please call the Information Line 
for up-to-date information on this meeting. A notice in the Federal 
Register about last minute modifications that impact a previously 
announced advisory committee meeting cannot always be published quickly 
enough to provide timely notice. Therefore, you should always check the 
agency's Web site and call the appropriate advisory committee hot line/
phone line to learn about possible modifications before coming to the 
    Agenda: The Science Board will hear about and discuss the agency's 
critical path program. The Science Board will hear about and discuss 
updates on the National Antimicrobial Resistance Monitoring System 
(NARMS) Program and activities related to melamine from the March 31, 
2006, and June 14, 2007, Science Board meetings. The Science Board will 
then hear about and discuss the subcommittee review of the agency's 
science programs. The Science Board will also hear about and discuss 
the agency's updates on drug safety.FDA intends to make background 
material available to the public no later than 2 business days before 
the meeting. If FDA is unable to post the background material on its 
Web site prior to the meeting, the background material will be made 
publicly available at the location of the advisory committee meeting, 
and the background material will be posted on FDA's Web site after the 
meeting. Background material is available at http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leavingFR.html&log=linklog&to=http://www.fda.gov/ohrms/dockets/ac/acmenu.htm
, click on the year 2007 and scroll down to the 

appropriate advisory committee link.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person on or before 
October 15, 2007. Oral presentations from the public will be scheduled 
between approximately 4 p.m. and 5 p.m. Those desiring to make formal 
oral presentations should notify the contact person and submit a brief 
statement of the general nature of the evidence or arguments they wish 
to present, the names and addresses of proposed participants, and an 
indication of the approximate time requested to make their presentation 
on or before October 5, 2007. Time allotted for each presentation may 
be limited. If the number of registrants requesting to speak is greater 
than can be reasonably accommodated during the scheduled open public 
hearing session, FDA may conduct a lottery to determine the speakers 
for the scheduled open public hearing session. The contact person will 
notify interested persons regarding their request to speak by October 
8, 2007.

[[Page 56079]]

    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Dr. Carlos 
Pe[ntilde]a at least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee 
meetings. Please visit our Web site at http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leavingFR.html&log=linklog&to=http://www.fda.gov/oc/advisory/default.htm
 for procedures on public conduct during advisory committee 

    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: September 23, 2007.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E7-19349 Filed 10-1-07; 8:45 am]